search
Back to results

Antidepressant Mechanisms of Transcranial Magnetic Stimulation

Primary Purpose

Depression

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Repetitive transcranial magnetic stimulation
Sponsored by
Weill Medical College of Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Magnetic stimulation of the brain, Antidepressant mechanisms

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A history of major depressive disorder by the Structured Clinical Interview for DSM-IV (SCID)
  2. Failure to respond to at least two previous antidepressant trials at adequate doses for 8 weeks (for current or prior major depressive episodes)
  3. A minimum 17-item Hamilton depression rating scale of 17 on both the screening day and the treatment day #1
  4. Age 18-70
  5. Participants may be taking antidepressants, antipsychotics, or low-dose mood stabilizers during the study
  6. Participants may be in psychotherapy during the study

Exclusion Criteria:

  1. Participants with metal implants (Will use the NY Presbyterian Hospital MRI Checklist)
  2. Prior exposure to TMS
  3. Pregnant women
  4. Lactating women
  5. Bipolar disorder (on the Structured Clinical Interview for DSM-IV (SCID)
  6. Current depressive episode longer than 3 years
  7. Active suicidal ideation with plan or intent
  8. Borderline personality disorder (on the Structured Clinical Interview for DSM-IV (SCID)
  9. Substance abuse or dependence with the past 3 years
  10. Current urine drug screen positive for any drugs of abuse
  11. Current symptoms of psychosis
  12. History of seizure disorder
  13. History of closed head injury with loss of consciousness
  14. History of brain surgery

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Active rTMS

    Arm Description

    Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.

    Outcomes

    Primary Outcome Measures

    Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)
    The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.

    Secondary Outcome Measures

    Depression Severity Measured by the Public Health Questionnaire-9
    Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).

    Full Information

    First Posted
    May 28, 2015
    Last Updated
    August 9, 2018
    Sponsor
    Weill Medical College of Cornell University
    Collaborators
    National Alliance for Research on Schizophrenia and Depression, Neuronetics
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02466230
    Brief Title
    Antidepressant Mechanisms of Transcranial Magnetic Stimulation
    Official Title
    Predictive and Response Biomarkers of Effective Treatment With Transcranial Magnetic Stimulation for Major Depressive Disorder
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2011 (undefined)
    Primary Completion Date
    October 2013 (Actual)
    Study Completion Date
    October 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Weill Medical College of Cornell University
    Collaborators
    National Alliance for Research on Schizophrenia and Depression, Neuronetics

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study utilizes resting state fMRI, arterial spin labelling imaging, diffusion tensor imaging, structural MR-imaging, and MR-spectroscopy of GABA and Glutamate to probe the antidepressant mechanisms of repetitive transcranial magnetic stimulation (rTMS). The above imaging modalities will be acquired before and after an open-label 5 week course of rTMS for depression in currently depressed individuals with treatment resistant depression. Changes in functional, structural, and neurochemical markers will be investigated in rTMS responders and nonresponders to elucidate mechanisms of plasticity that correlate with treatment response. Additionally, functional, structural, and neurochemical signatures at baseline that correlate with subsequent treatment response will be investigated.
    Detailed Description
    Repetitive Transcranial Magnetic Stimulation (rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) alleviates mood in major depression. This treatment received FDA approval in 2009 and is now in routine clinical use for the treatment of major depression. A recently published sham-controlled study showed a response rate of 14% in real rTMS compared to 5% in sham rTMS. The response, defined by a greater than 50% reduction in the Hamilton Depression Rating Scale from pre-treatment to post-treatment, was also found to be 14% in one recent meta-analysis. The inclusion criteria in these studies admitted a broad spectrum of participants, ranging from subjects having a first major depressive episode, to those having failed multiple medication trials, suggesting that a subgroup with a more robust response may be masked by an unresponsive group. Abnormal function of the left frontal lobe accompanies major depression and this may be normalized by rTMS Cerebral blood flow measured with SPECT imaging was reduced in the left DLPFC of depressed subjects and was increased during and after a course of rTMS over the left DLPFC. Decreased blood flow was found in a broader region of frontal and paralimbic regions in depressed individuals and treatment success was associated with decreased blood flow in the inferior frontal lobes both pre- and post- treatment. Greater post-treatment vs. pre-treatment BOLD activation of left frontal regions was demonstrated using fMRI in a planning task that engages the frontal lobes. Left prefrontal myo-inositol is reduced in depressed subjects and this is normalized by rTMS. The above functional abnormalities view the frontal lobe in isolation. However, recent work has demonstrated a network-based structural marker of risk for familial depression consisting of decreased cortical and white mater volume. Resting state fMRI (rs-fMRI) tests cross-regional temporal coherence in low frequency oscillations in brain responses (~0.1 Hz) that are believed to represent spontaneous neural activity. Correlated spontaneous fluctuations are understood to reflect functional connections between brain regions that arise through a history of co-activation across one's lifetime. Previous work has shown that depressed patients exhibit altered functional connectivity patterns as gauged by rs-fMRI, and some studies suggest that these differences may be mitigated by treatment with antidepressant medications. However, whether and how TMS may affect functional connectivity is unknown. I propose to acquire the several described MRI types both before and after rTMS treatment in a search for predictive markers of rTMS treatment success as well as markers of treatment-induced change. Arterial spin labeling will be acquired to measure the blood flow distribution throughout the brain, both to confirm the SPECT results already reported and to test for additional regions of change. Resting state fMRI will be collected and DTI will be used to explore the structural basis of functional network changes. Structural MRI will be collected to measure cortical thickness and white matter volumes that may be predictive of rTMS response. Magnetic resonance spectroscopy will be collected to confirm the previously reported finding of rTMS-induced myo-inositol changes, as well as to consider the Glutamate/Glutamine and GABA spectra, given the importance of these neurotransmitters in theories of depression.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Depression
    Keywords
    Magnetic stimulation of the brain, Antidepressant mechanisms

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    28 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Active rTMS
    Arm Type
    Experimental
    Arm Description
    Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
    Intervention Type
    Device
    Intervention Name(s)
    Repetitive transcranial magnetic stimulation
    Intervention Description
    Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
    Primary Outcome Measure Information:
    Title
    Depression Severity Measured by the Hamilton Depression Rating Scale (24-Item)
    Description
    The Hamilton Depression Rating Scale is 24 items with total scores ranging from 0-76. Higher scores indicate greater severity of depression. (0-7 = None; 8-13 = Mild; 14-18 = Moderate; 19-23 = Severe; 23 and higher = very severe). Total scores are reported with no subscales.
    Time Frame
    Change in score on Hamilton Depression Rating Scale from baseline to immediately after the final rTMS treatment (5 weeks)
    Secondary Outcome Measure Information:
    Title
    Depression Severity Measured by the Public Health Questionnaire-9
    Description
    Self-rated scale of symptoms of depression. Nine items with a maximum score of 27. Higher score means more severe depression (0-4 = None; 5-9 = Mild; 10-14 = Moderate; 15-19 = Severe; 20 and higher = Very Severe).
    Time Frame
    Change in score in Public Health Questionnaire-9 from baseline to immediately after the final rTMS treatment (5 weeks)
    Other Pre-specified Outcome Measures:
    Title
    Gamma-amino-butyric Acid Level Measured by Magnetic Resonance Spectroscopy
    Description
    Percent change in medial prefrontal gamma-amino-butyric acid level
    Time Frame
    Baseline to immediately after the final rTMS treatment (5 weeks)
    Title
    Glutamate Level Measured by Magnetic Resonance Spectroscopy
    Description
    Percent change in medial prefrontal glutamate level
    Time Frame
    Baseline to immediately after the final rTMS treatment (5 weeks)
    Title
    Cortical Thickness Measured by T1 Magnetic Resonance Imaging
    Description
    Percent change in medial prefrontal average cortical thickness
    Time Frame
    Baseline to immediately after the final rTMS treatment (5 weeks)
    Title
    Fractional Anisotropy Measured by Diffusion Tensor Imaging
    Description
    Percent change in medial prefrontal average fractional anisotropy
    Time Frame
    Baseline to immediately after the final rTMS treatment (5 weeks)
    Title
    Functional Connectivity Measured by Functional Magnetic Resonance Imaging
    Description
    Percent change in medial prefrontal average functional connectivity
    Time Frame
    Baseline to immediately after the final rTMS treatment (5 weeks)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A history of major depressive disorder by the Structured Clinical Interview for DSM-IV (SCID) Failure to respond to at least two previous antidepressant trials at adequate doses for 8 weeks (for current or prior major depressive episodes) A minimum 17-item Hamilton depression rating scale of 17 on both the screening day and the treatment day #1 Age 18-70 Participants may be taking antidepressants, antipsychotics, or low-dose mood stabilizers during the study Participants may be in psychotherapy during the study Exclusion Criteria: Participants with metal implants (Will use the NY Presbyterian Hospital MRI Checklist) Prior exposure to TMS Pregnant women Lactating women Bipolar disorder (on the Structured Clinical Interview for DSM-IV (SCID) Current depressive episode longer than 3 years Active suicidal ideation with plan or intent Borderline personality disorder (on the Structured Clinical Interview for DSM-IV (SCID) Substance abuse or dependence with the past 3 years Current urine drug screen positive for any drugs of abuse Current symptoms of psychosis History of seizure disorder History of closed head injury with loss of consciousness History of brain surgery
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Marc J Dubin, MD, PhD
    Organizational Affiliation
    Weill Medical College of Cornell University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Antidepressant Mechanisms of Transcranial Magnetic Stimulation

    We'll reach out to this number within 24 hrs